Hubbry Logo
Motor disorderMotor disorderMain
Open search
Motor disorder
Community hub
Motor disorder
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Motor disorder
Motor disorder
Motor disorder
View on Wikipedia
from Wikipedia
Motor disorder
SpecialtyNeurology

Motor disorders are disorders of the nervous system that cause abnormal and involuntary movements. They can result from damage to the motor system.[1]

Motor disorders are defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – published in 2013 to replace the fourth text revision (DSM-IV-TR) – as a new sub-category of neurodevelopmental disorders. The DSM-5 motor disorders include developmental coordination disorder, stereotypic movement disorder, and the tic disorders including Tourette syndrome.[2]

Signs and symptoms

[edit]

Motor disorders are malfunctions of the nervous system that cause involuntary or uncontrollable movements or actions of the body.[3] These disorders can cause lack of intended movement or an excess of involuntary movement.[4] Symptoms of motor disorders include tremors, jerks, twitches, spasms, contractions, or gait problems.[citation needed]

Tremor is the uncontrollable shaking of an arm or a leg. Twitches or jerks of body parts may occur due to a startling sound or unexpected, sudden pain. Spasms and contractions are temporary abnormal resting positions of hands or feet. Spasms are temporary while contractions could be permanent. Gait problems are problems with the way one walks or runs. This can mean an unsteady pace or dragging of the feet along with other possible irregularities.[3]

Causes

[edit]

Pathological changes of certain areas of the brain are the main causes of most motor disorders.[4] Causes of motor disorders by genetic mutation usually affect the cerebrum.[5] The way humans move requires many parts of the brain to work together to perform a complex process. The brain must send signals to the muscles instructing them to perform a certain action. There are constant signals being sent to and from the brain and the muscles that regulate the details of the movement such as speed and direction, so when a certain part of the brain malfunctions, the signals can be incorrect or uncontrollable causing involuntary or uncontrollable actions or movements.[4]

Diagnosis

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Motor disorder

View on Grokipedia
from Grokipedia
Movement disorders are a diverse group of neurological conditions that disrupt the nervous system's control over voluntary and involuntary movements, leading to either excessive, uncontrolled motions (hyperkinetic disorders) or reduced, slowed, or absent movements (hypokinetic disorders). These disorders arise from dysfunction in brain regions such as the , , or , and can significantly impact daily activities, balance, coordination, and . Common types of movement disorders include ataxia, characterized by loss of muscle coordination resulting in clumsy or unsteady movements; dystonia, involving sustained or intermittent muscle contractions that cause twisting, repetitive, or painful postures; Parkinson's disease, a progressive hypokinetic disorder featuring tremors, rigidity, bradykinesia (slowness of movement), and postural instability; chorea, marked by rapid, jerky, involuntary movements as seen in Huntington's disease; tremor, such as essential tremor causing rhythmic shaking; and Tourette syndrome, which involves tics combining motor and vocal outbursts. Symptoms vary widely but often encompass involuntary jerks, spasms, slowed gait, balance problems, or difficulty with fine motor tasks like writing or buttoning clothes. The causes of movement disorders are multifaceted and can include genetic factors, as in inherited conditions like ; exposure to certain medications, toxins, or illegal drugs; underlying medical issues such as , , infections, or autoimmune diseases; nutritional deficiencies (e.g., vitamins B1, B12, or E); or head trauma. In many cases, particularly with , the exact cause remains idiopathic, though aging and environmental influences play roles. Although some movement disorders are progressive and incurable, early intervention can help manage symptoms and enhance independence.

Definition and Classification

Definition

Motor disorders, also known as , are a group of neurological conditions characterized by impaired voluntary resulting from dysfunction in the central or , which disrupts the initiation, execution, or coordination of movements. These disorders arise from damage or disease affecting key components of the , including upper and lower motor neurons, , or , leading to abnormal involuntary movements, reduced mobility, or altered . Unlike broader neurological impairments, motor disorders primarily target the pathways responsible for muscle activity and posture, without inherently involving primary deficits in sensation or . The concept of motor disorders evolved in the alongside the emergence of modern as a discipline. Early descriptions date to the mid-1800s, with French neurologist playing a pivotal role through his anatomoclinical method, which correlated clinical symptoms with postmortem findings to delineate specific motor pathologies. provided foundational accounts of conditions like (ALS) in 1865, distinguishing its progressive motor neuron degeneration, and refined understandings of and , emphasizing motor symptoms such as and . By the late , these efforts had cataloged numerous motor disturbances, laying the groundwork for classifying them as distinct from other ailments. Key inclusion criteria for motor disorders focus on conditions where motor function is the primary domain affected, such as (sustained muscle contractions causing twisting postures), (impaired coordination and balance), and (velocity-dependent increase in ). These are identified by their predominant impact on voluntary movement without a primary loss of sensory input, though secondary sensory changes may occur. In contrast, motor disorders are differentiated from sensory disorders, which impair of stimuli like touch or vision, and cognitive disorders, which affect memory, reasoning, or executive function, as the former specifically compromise the neural circuits governing action rather than or thought.

Classification

Motor disorders are systematically classified into primary categories based on the nature of motor dysfunction, distinguishing between hyperkinetic disorders, which involve excessive or involuntary movements such as and tremors, and hypokinetic disorders, characterized by reduced or slowed movements like those seen in . This aids in clinical differentiation and guides targeted interventions, with hyperkinetic examples including and , while hypokinetic conditions often manifest as bradykinesia and rigidity. Another fundamental classification separates central motor disorders, which originate in the or (e.g., resulting from early injury), from peripheral motor disorders, which affect nerves, s, or muscles (e.g., involving antibody-mediated disruption at the ). These distinctions facilitate etiological assessment and treatment by localizing the site of within the . International standards provide structured coding for motor disorders to support global and . In the , motor-related conditions fall under the broad chapter on diseases of the (code 08), with dedicated blocks for (8A00–8A0Z, encompassing [8A00], dystonic disorders [8A02], ataxic disorders [8A03], and tic disorders [8A05]), (e.g., under 8B60), and neuromuscular junction or muscle disorders (8C20–8C4Z). The DSM-5 overlaps with these by classifying certain motor disorders as neurodevelopmental, including (impaired motor skill acquisition), (repetitive, purposeless movements), and tic disorders such as Tourette's disorder (combined motor and vocal tics persisting beyond a year), highlighting intersections between psychiatric and neurological frameworks. Major subtypes of motor disorders include the following, each with distinct brief characteristics for diagnostic and research purposes (noting that broader categories like neuromuscular and are related but often classified separately):
  • Movement disorders: Encompass abnormal regulation of voluntary and involuntary movements, subdivided into hyperkinetic (e.g., with irregular, flowing motions) and hypokinetic (e.g., with paucity of movement) forms, often linked to dysfunction.
  • Ataxic disorders: Feature impaired coordination and balance due to cerebellar or sensory pathway involvement, resulting in unsteady and .
  • Dystonic disorders: Characterized by sustained or intermittent muscle contractions causing twisting postures or repetitive movements, often task-specific (e.g., ).
  • Tic disorders: Involve sudden, rapid, repetitive motor or vocal actions, ranging from simple (e.g., eye ) to complex (e.g., gesturing), with waxing and waning patterns.
  • Myoclonic disorders: Marked by brief, shock-like jerks, which may be isolated or part of syndromes like progressive myoclonic , stemming from cortical or subcortical hyperexcitability.
Emerging classifications in the 2020s integrate genetic versus idiopathic subtypes, driven by genomic advancements like next-generation sequencing, which has identified causative mutations in approximately 20% of previously idiopathic cases, enabling precision subclassification (e.g., genetic via or GBA variants versus sporadic forms). This shift refines diagnostic criteria and supports targeted therapies, such as gene-specific interventions for hereditary ataxias or dystonias. As of 2025, advances include gene therapies like AB-1005 for , which are progressing through clinical trials.

Signs and Symptoms

General Presentation

Motor disorders are characterized by a range of observable abnormalities in voluntary and involuntary movements, affecting posture, gait, fine motor skills, and overall motor control. Patients often present with irregular or twisted postures due to sustained involuntary muscle contractions, unsteady or shuffling gaits that compromise balance and propulsion, diminished fine motor precision leading to difficulties in tasks requiring dexterity, and features such as muscle rigidity or bradykinesia, which manifest as stiffness and slowness in movement initiation and execution. These core manifestations can encompass both hyperkinetic elements, like tremors or jerks, and hypokinetic features, such as reduced movement amplitude, highlighting the spectrum of motor dysfunction across disorders. Progression patterns in motor disorders vary between acute and chronic trajectories, influencing how symptoms unfold over time. Acute onset typically involves a sudden emergence of motor abnormalities, which may stabilize, partially resolve, or persist depending on the precipitating factors, often requiring prompt intervention to mitigate long-term effects. In contrast, chronic progression is marked by a gradual intensification of symptoms over months to years, evolving from mild disruptions to more pervasive impairments that increasingly limit independence. Symptoms generally advance through phases of subtle early changes to pronounced functional deficits, with potential fluctuations or temporary plateaus reflecting underlying neural adaptations or external influences. The functional consequences of motor disorders profoundly affect daily activities, particularly mobility, dexterity, and . Impaired and balance heighten the risk of falls and restrict ambulation, while compromised fine motor skills hinder routine actions such as eating, dressing, or manipulating objects. Speech may become slurred or effortful due to weakened or uncoordinated oral muscles, complicating communication. Globally, neurological conditions encompassing motor disorders impact over 3 billion people and represent the primary cause of and ill , with disability-adjusted life years (DALYs) increasing by 18% since 1990, underscoring their substantial contribution to health loss. Beyond observable motor deficits, patients frequently describe secondary experiences of and that amplify the burden of these disorders. often presents as pervasive whole-body exhaustion or reversible triggered by physical exertion, diminishing endurance for everyday tasks. , stemming from chronic muscle tension, spasms, or atypical postures, can be musculoskeletal or neuropathic, further eroding and motivation. These patient-reported aspects highlight the holistic toll of motor impairments on .

Specific Manifestations

Motor disorders exhibit diverse subtype-specific manifestations, reflecting underlying disruptions in neural circuits. In , symptoms typically involve sustained or intermittent muscle contractions that produce twisting and repetitive movements or abnormal postures, often affecting specific body regions such as the neck in cervical dystonia or the eyelids in . These contractions arise from co-activation of and muscles, leading to forceful distortions that can interfere with daily activities like writing in task-specific forms such as . Anatomically, correlates with dysfunction in the , including microstructural changes in the and , as well as altered activity in the pars reticulata. Ataxia, another key subtype, is characterized by impaired coordination and balance due to cerebellar involvement, manifesting as unsteady with widened base, limb (overshooting targets during movements), and that worsens with purposeful actions. Patients often display and loss of check, where movements fail to adjust smoothly, resulting in jerky or irregular trajectories. Cerebellar lesions produce ipsilateral symptoms, such as in the affected limbs, underscoring the region's role in fine-tuning motor output. Associated features may include subtle balance deficits that exacerbate motor instability, as seen in variability and reduced ankle motion. Tremors represent rhythmic, oscillatory movements that vary by subtype, with essential tremor featuring bilateral postural or kinetic oscillations primarily in the upper limbs at frequencies of 4-12 Hz, often worsening with action. In parkinsonian tremor, a classic resting manifestation involves low-frequency (4-6 Hz) "pill-rolling" motions of the hands, simulating rolling a pill between and forefinger, which diminishes with voluntary movement. These patterns correlate with cerebello-thalamo-cortical and circuits, where pathological synchrony in the subthalamic nucleus and contributes to the oscillations. Dystonic tremor, blending irregular postures with rhythmic components, frequently involves the head or voice and links to overlapping and cerebellar networks. Other hyperkinetic manifestations include , characterized by brief, irregular, rapid, involuntary movements that appear dance-like and often involve the face, mouth, hands, or feet, as commonly seen in . Tics in consist of sudden, brief, repetitive motor movements or vocalizations, such as eye blinking, facial grimacing, shoulder shrugging, or throat clearing, which can be simple or complex and are often preceded by a . Non-motor features tied to motor expression can include mild autonomic changes, such as abnormal sweating during episodes, which may heighten discomfort and influence . In , subtle sensory-motor integration issues, like impaired , amplify coordination loss without dominating the presentation. Age-related variations influence symptom profiles; pediatric-onset motor disorders, such as early generalized , often present with developmental delays and widespread limb involvement starting before age 6, contrasting with adult-onset forms like emerging after 20 with localized, progressive twisting. Ataxic syndromes in children may manifest as delayed motor milestones and instability from infancy, while adult cases typically show insidious progression with weakness and falling risks increasing over decades. Tremors in youth can appear as task-specific action types, whereas adult introduces resting components alongside rigidity, with onset commonly after 50. Diagnostic red flags aid in subtype identification; the "pill-rolling" rest in signals involvement, while and in point to cerebellar , and irregular, posture-inducing oscillations distinguish dystonic tremor from essential forms.

Causes and Risk Factors

Genetic Factors

Genetic factors contribute substantially to the development of motor disorders, often through monogenic patterns that disrupt neuronal function and . These disorders frequently arise from mutations in genes critical for neuronal integrity, synaptic transmission, and protein , leading to progressive motor impairments such as , , and . Autosomal dominant predominates in many cases, where a single mutated suffices to cause , though recessive patterns occur in others involving biallelic variants. Prominent examples include , an autosomal dominant neurodegenerative disorder characterized by expanded CAG trinucleotide repeats in the gene on , resulting in elongated polyglutamine tracts in the protein that aggregate and impair striatal neurons. Typically, alleles with 36 or more CAG repeats confer full , with repeat length correlating inversely with age of onset—juvenile cases often exceed 60 repeats. Spinocerebellar ataxias (SCAs), another group of autosomal dominant motor disorders, similarly involve polyglutamine expansions from CAG repeats in genes such as ATXN3 (SCA3/Machado-Joseph disease), ATXN1 (SCA1), and ATXN7 (SCA7); these expansions disrupt cerebellar Purkinje cells and spinocerebellar pathways, causing progressive , , and oculomotor abnormalities. In contrast, some motor disorders like certain forms of follow autosomal recessive inheritance, involving biallelic mutations that compound loss-of-function effects. A range of mutation types underlies these conditions, including point mutations that alter protein coding sequences, copy number variations (CNVs) such as duplications or deletions affecting gene dosage, and epigenetic modifications like aberrant DNA methylation or histone acetylation that silence or dysregulate motor-related genes without changing the DNA sequence. For instance, CNVs in genes like SPAST (SPG4-linked spastic paraplegia) can lead to haploinsufficiency, while epigenetic alterations in promoters of dopamine-regulating genes contribute to variable expressivity in parkinsonian disorders. Recent CRISPR-based studies from 2023 to 2025 have demonstrated potential for targeted correction of these mutations; in Huntington's disease models, CRISPR/CasRx systems have significantly reduced mutant HTT mRNA in neuronal cultures and mouse brains, alleviating motor deficits without off-target effects. Similarly, CRISPR/Cas9 editing of the ATXN3 gene in spinocerebellar ataxia type 3 patient-derived cells has targeted the expanded repeats to suppress mutant protein expression by inserting polyadenylation signals, restoring normal protein levels and improving cellular viability. Penetrance—the proportion of carriers who manifest the disorder—and expressivity—the severity and variability of symptoms—highlight the of genetic contributions to motor phenotypes. In early-onset primary linked to the DYT1 locus (TOR1A ), a 3-base-pair GAG deletion in 5 yields torsinA protein misfolding, but is incomplete at around 30-40%, influenced by modifier genes and environmental interactions; affected individuals may exhibit focal limb progressing to generalized involvement, while non-penetrant carriers remain . This variability underscores how genetic background modulates motor outcomes, as seen in polyglutamine disorders where somatic repeat instability exacerbates progression. Advancements in have enhanced diagnostic precision for , with next-generation sequencing (NGS) enabling the detection of rare variants across hundreds of genes simultaneously. NGS panels targeting genes yield diagnostic rates of 20-40% in or early-onset cases, identifying causative mutations like those in PRKN for recessive or ATP1A3 for rapid-onset dystonia-, and facilitating personalized in families. Whole-exome sequencing further uncovers novel variants in undiagnosed patients, reducing the diagnostic and informing prognosis.

Environmental and Acquired Factors

Environmental and acquired factors play a significant role in the development of motor disorders, encompassing exposures to toxins, infections, trauma, and perinatal complications that disrupt neurological function without inherent . These factors often lead to motor impairments through direct , , or hypoxic damage to brain structures involved in movement control, such as the and . Unlike genetic causes, these are modifiable risks that highlight the importance of preventive measures in occupational, infectious, and obstetric settings. Toxin exposures, particularly to heavy metals like manganese, can induce parkinsonism resembling idiopathic Parkinson's disease but with distinct features such as early dystonia and less prominent tremor. Chronic manganese intoxication, often from occupational exposure in mining or welding, accumulates in the basal ganglia, causing manganism—a syndrome of bradykinesia, rigidity, and gait instability that may progress even after exposure cessation. In the 1980s, research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a contaminant in synthetic opioids, provided a seminal animal model for parkinsonism; intravenous MPTP in humans and primates selectively destroyed dopaminergic neurons in the substantia nigra, mimicking Parkinson's pathology and accelerating therapeutic drug development. Infectious causes contribute to motor disorders via direct viral invasion or post-infectious immune responses affecting the . The 1918 influenza pandemic was linked to , resulting in in survivors, characterized by oculomotor abnormalities, sleep disturbances, and progressive akinetic-rigid syndromes years after acute illness. Similarly, human immunodeficiency virus () infection is associated with distal symmetrical polyneuropathy, a predominantly sensory-motor neuropathy affecting up to 57% of patients, manifesting as distal weakness, paresthesias, and reduced reflexes due to axonal degeneration in peripheral nerves. Traumatic factors, especially (TBI), can precipitate spastic motor disorders by damaging upper motor neurons, leading to , , and impaired coordination. Moderate to severe TBI disrupts corticospinal tracts, resulting in spastic hemiparesis or quadriparesis in affected individuals. According to CDC data, there were approximately 69,000 TBI-related deaths and over 214,000 hospitalizations in the United States in 2020-2021, with falls and crashes as leading causes; survivors face elevated risks of long-term , particularly in younger populations. Developmental insults during the perinatal period, such as hypoxia, are major contributors to , a non-progressive motor disorder involving , , or . Perinatal hypoxia-ischemia accounts for approximately 10-20% of cases overall, with about 15% in moderate preterm infants (32-35 weeks gestation); it damages periventricular and . Premature birth before 37 weeks gestation amplifies this risk through immature vascular autoregulation and vulnerability to hypoxic episodes, with multiple births and further elevating odds by promoting respiratory distress and .

Pathophysiology

Neurological Basis

Motor disorders arise from disruptions in the , particularly involving the and , which impair the planning, initiation, and execution of voluntary movements. The , a group of subcortical nuclei including the , , subthalamic nucleus, and , play a central role in such as and by modulating motor circuits through inhibitory and excitatory projections. These structures receive inputs from the and , processing signals to facilitate smooth movement selection while suppressing unwanted actions. In parallel, the contributes to by fine-tuning ongoing movements, integrating sensory feedback, and predicting error corrections via its Purkinje cells and deep nuclei. Cerebellar pathology, as seen in ataxias, leads to and gait instability due to impaired predictive control of limb trajectories. A key feature of these disruptions is the degeneration of , particularly the nigrostriatal tract originating from the to the dorsal . In , this pathway shows progressive loss, visualized in schematic diagrams as interrupted axonal projections from melanin-containing neurons in the nigra to striatal medium spiny neurons, resulting in reduced signaling that biases motor output toward rigidity and bradykinesia. Symptoms typically emerge after approximately 50-60% loss of nigral neurons, corresponding to about 80% depletion of striatal , highlighting a threshold effect in pathway integrity. imbalances further exacerbate these issues; for instance, depletion in the disrupts the balance between excitatory and inhibitory signals, while in , reduced inhibition and altered glutamate release in sensorimotor circuits lead to excessive muscle contractions. Specifically, thalamic GABA levels are significantly lowered in cervical patients, with GABA/glutamate ratios decreased by up to 20-30% compared to controls, contributing to hyperexcitability in downstream motor pathways. At the circuit level, motor disorders involve dysfunction in the basal ganglia-thalamocortical loops, which operate through parallel direct and indirect pathways to regulate cortical motor areas. The direct pathway, comprising D1 receptor-expressing striatal neurons projecting to the internal (GPi) and pars reticulata (SNr), disinhibits the ventral anterior/ventrolateral to promote movement initiation via glutamatergic projections back to the cortex. In contrast, the indirect pathway, involving D2 receptor-expressing neurons that connect to the external (GPe) and subthalamic nucleus (STN), increases GPi/SNr inhibition of the , thereby suppressing competing movements; dopaminergic modulation from the enhances direct pathway activity while inhibiting the indirect one. Imbalances in these loops, such as overactivity of the indirect pathway in Parkinson's due to loss, result in thalamic hypoactivity and reduced cortical drive for fluid motion. Recent studies using functional MRI (fMRI) have revealed altered connectivity patterns in ataxias, underscoring cerebellar involvement in broader network disruptions. These findings highlight how central pathway alterations propagate to affect output indirectly through descending tracts.

Peripheral Mechanisms

Peripheral mechanisms in motor disorders involve disruptions at the , peripheral nerves, and skeletal muscles, leading to impaired motor function distinct from processes. At the , defects primarily manifest in conditions like (MG), where autoantibodies target acetylcholine receptors (AChRs), reducing their density and functionality. These antibodies, present in approximately 85% of MG patients, bind to AChRs on the postsynaptic membrane, triggering multiple pathogenic effects that culminate in fatigable . The key mechanisms include complement-mediated destruction of the postsynaptic membrane, antigenic modulation through cross-linking and accelerated internalization of AChRs, and direct blockade of binding sites. Complement by IgG1 and IgG3 subclasses damages the endplate, while cross-linking increases AChR degradation rates, often reducing receptor numbers by 50-75% in affected muscles. This impaired neuromuscular transmission results in fluctuating weakness that worsens with repetitive activity, as fewer functional receptors fail to sustain endplate potentials during sustained muscle use. In peripheral neuropathies associated with motor disorders, such as (ALS), axonal degeneration affects lower motor neurons, leading to and . ALS pathology includes progressive loss of motor axons in peripheral nerves, with histopathological hallmarks like Bunina bodies—eosinophilic cytoplasmic inclusions composed of neurofilaments and organelles—observed in degenerating anterior horn cells and residual motor neurons. These inclusions, unique to ALS, reflect and cytoskeletal disruption during failure, contributing to Wallerian-like degeneration distally. Although sensory nerves are typically spared, motor axon loss can involve up to 20% of cases showing subclinical sensory involvement, but the primary motor deficit arises from this peripheral axonal pathology. Muscle pathology in motor disorders often stems from intrinsic defects, as seen in muscular dystrophies like (DMD), caused by deficiency. stabilizes the during contraction; its absence leads to membrane fragility, calcium influx, and cycles of fiber and regeneration. This results in histopathological changes including centralized nuclei, variation in fiber size, and shifts in fiber type composition, with a notable decrease in type 2A fast-twitch fibers in affected muscles. Progressive replaces functional myofibers with , driven by transforming growth factor-beta (TGF-β) signaling and fibrogenic cell proliferation, ultimately reducing muscle contractility and leading to in early stages followed by severe wasting. Electrophysiological correlates of these peripheral mechanisms provide diagnostic insights into motor disorders. In MG, repetitive nerve stimulation reveals a characteristic decrement in (CMAP) amplitude greater than 10% at low frequencies (2-5 Hz), reflecting impaired neuromuscular transmission, while single-fiber shows increased jitter due to variable synaptic delays. In , nerve conduction studies typically show normal velocities but reduced CMAP amplitudes from axonal loss, with motor nerve conduction velocities occasionally dropping below 40 m/s in advanced multifocal involvement, alongside electromyographic denervation patterns like fibrillation potentials. For muscular dystrophies like DMD, nerve conduction velocities remain normal, but myopathic changes on include small, polyphasic potentials and early recruitment, without significant conduction slowing unless secondary neuropathy coexists. These findings underscore peripheral disruptions without primary demyelination in most cases.

Diagnosis

Clinical Assessment

The clinical assessment of motor disorders commences with a thorough history-taking to establish the temporal profile, , and impact of symptoms. Key elements include inquiring about the onset (sudden versus insidious), progression (static, improving, or worsening), associated features like or sensory changes, family history of similar conditions, and exposure to potential triggers such as medications or toxins. Functional impact is quantified through patient-reported questionnaires, such as the Unified Parkinson's Disease Rating Scale (UPDRS) for parkinsonian features, which evaluates experiences of daily living affected by motor symptoms. The physical examination emphasizes observational and targeted maneuvers to characterize motor abnormalities. Clinicians observe spontaneous movements, posture, and for asymmetries, bradykinesia, or instability, followed by assessment of to distinguish rigidity (lead-pipe or cogwheel) from (velocity-dependent). Coordination is tested via maneuvers like the finger-to-nose or heel-to-shin tests to detect or . A structured differential diagnosis framework guides the evaluation to exclude mimics, particularly psychogenic disorders, through bedside tests demonstrating inconsistency or distractibility. For instance, the Hoover sign—assessing involuntary leg extension during attempted hip flexion—can indicate functional weakness if positive, while entrainment tests for reveal variability not seen in organic conditions. Reported manifestations, such as or , are corroborated during this exam to align history with observed signs. Standardized scales provide objective quantification of severity. The Movement Disorder Society-sponsored revision of the UPDRS (MDS-UPDRS) comprises 50 items across four parts—non-motor daily living (0-52), motor daily living (0-52), motor examination (0-132), and motor complications (0-24)—with most items scored 0-4 (0=normal, 4=severe), yielding a total range of 0-260; scores below 30 often indicate mild disease. For , the International Cooperative Ataxia Rating Scale (ICARS) assesses 19 items in four subscales (posture/gait: 0-34, kinetic functions: 0-52, speech: 0-8, oculomotor: 0-6), with a total score of 0-100 where higher values reflect greater impairment.

Imaging and Laboratory Tests

Magnetic resonance imaging (MRI) serves as a primary tool for identifying structural abnormalities in motor disorders, particularly in degenerative s where it reveals patterns of cerebellar . In hereditary s such as spinocerebellar s, conventional MRI demonstrates diffuse cerebellar volume loss, often affecting the anterior vermis and , without associated T2-weighted signal hyperintensities. Quantitative MRI techniques further quantify these atrophic changes, aiding in the differentiation of subtypes by assessing cortical cerebellar or spinal involvement. Dopamine transporter (DaT) imaging, commonly performed via single-photon emission computed tomography (SPECT) using DaTscan, is essential for confirming presynaptic dopaminergic deficits in parkinsonian motor disorders. In , DaTscan shows reduced uptake in the due to loss of proteins, distinguishing it from non-degenerative conditions like where uptake remains normal. This imaging modality supports but does not differentiate between and other synucleinopathies such as . Genetic testing through targeted panels is crucial for diagnosing hereditary motor disorders, analyzing multiple genes associated with conditions like hereditary motor neuropathies. Panels such as the Inherited Motor Neuropathy Gene Panel sequence up to 24 genes, detecting variants in genes like those implicated in Charcot-Marie-Tooth disease, to confirm molecular diagnoses and guide family screening. These tests provide high sensitivity for single nucleotide variants and copy number changes, facilitating precise identification of autosomal dominant or recessive forms. Cerebrospinal fluid (CSF) analysis evaluates inflammatory markers in acquired motor disorders, particularly those with autoimmune or neurodegenerative components affecting motor neurons. In , elevated CSF levels of and interleukin-8 correlate with motor impairment severity, while levels are also elevated in , indicating neuroinflammatory processes. This analysis helps differentiate inflammatory etiologies from purely degenerative ones by measuring cytokines and complement components. Electrophysiological studies, including (EMG) and nerve conduction studies (NCS), assess peripheral motor involvement in disorders like (ALS). In ALS, needle EMG reveals active with fibrillation potentials and chronic reinnervation signs, such as reduced recruitment and large potentials, distributed across multiple spinal regions. NCS typically show normal sensory responses but reduced compound muscle action potentials in affected motor nerves, confirming pathology while excluding peripheral neuropathies. Recent advancements in biomarkers include blood-based assays for , with 2025 clinical trials validating their diagnostic utility. Seeding amplification assays detect misfolded aggregates in plasma with high , enabling earlier identification of synucleinopathies compared to CSF measures. These assays support patient stratification in trials and monitoring of disease progression, as demonstrated in ongoing studies emphasizing for clinical .

Treatment and Management

Pharmacological Approaches

Pharmacological approaches to motor disorders primarily target imbalances in the and motor neurons to alleviate symptoms such as bradykinesia, rigidity, and . These treatments include symptomatic relief agents and disease-modifying drugs, with efficacy varying by disorder type, such as hypokinetic conditions like or hyperkinetic ones like . Dopaminergic agents, particularly levodopa, serve as the cornerstone for managing hypokinetic motor disorders like by acting as a precursor to , crossing the blood-brain barrier to replenish depleted levels in the . Administered often with carbidopa to prevent peripheral , levodopa improves motor symptoms but can lead to levodopa-induced dyskinesias (), characterized by involuntary movements, after prolonged use due to pulsatile stimulation. Additionally, long-term therapy may cause "wearing-off" effects, where symptom reemergence occurs as plasma levels decline, affecting up to 50% of patients within five years. For , a hyperkinetic motor disorder, drugs like are commonly used to restore balance between and activity in the by blocking muscarinic receptors, thereby reducing involuntary muscle contractions. Dosing typically starts at 1 mg daily, titrated gradually by 2 mg every three to five days to a maintenance range of 5-15 mg per day in divided doses, though higher doses up to 30-40 mg daily may be required for generalized in select cases, with response often delayed for weeks to months. agents, such as , may complement by enhancing inhibitory neurotransmission via GABA-B receptors, though evidence is more limited for compared to spasticity-dominant disorders.

Non-Pharmacological Interventions

Non-pharmacological interventions for motor disorders encompass a range of surgical, therapeutic, and lifestyle approaches aimed at improving motor function, reducing symptoms, and enhancing . These strategies are particularly valuable for conditions like , , and stroke-related impairments, often serving as adjuncts to pharmacological treatments by addressing functional limitations directly. Evidence from randomized controlled trials (RCTs) and meta-analyses supports their efficacy in targeting , balance, and daily activities, with benefits persisting beyond short-term applications. Surgical options, such as (DBS), represent a cornerstone intervention for advanced motor disorders, especially . DBS involves implanting electrodes in the subthalamic nucleus (STN) to deliver electrical impulses that modulate abnormal neural activity, leading to significant symptom relief. Clinical studies report that STN-DBS reduces Unified Parkinson's Disease Rating Scale (UPDRS) motor scores by 47-71% in the off-medication state, with improvements in rigidity, bradykinesia, and sustained for up to 8-15 years in long-term follow-ups. A of DBS outcomes confirms these reductions, highlighting a 50-70% overall symptom improvement while noting potential risks like or hardware complications in 5-10% of cases. Rehabilitation therapies, including physical and occupational therapy, provide structured, evidence-based support for motor recovery. Physical therapy focuses on gait training through techniques like treadmill walking or virtual reality-assisted exercises, which have demonstrated improvements in gait variability, symmetry, and balance in patients with Parkinson's and stroke. For instance, RCTs show that robot-assisted gait training enhances walking smoothness and reduces fall risk by 20-30% compared to conventional methods, with benefits evident after 4-6 weeks of sessions. Occupational therapy complements this by prescribing adaptive devices such as reachers, button hooks, or customized wheelchairs, which promote independence in self-care and mobility; systematic reviews indicate these interventions improve functional performance by 25-40% in children and adults with motor deficits from neurological conditions. Assistive technologies, including exoskeletons and , have advanced rapidly to support motor function in individuals with severe impairments. Powered exoskeletons, such as overground wearable robots, assist with ambulation by providing to lower limbs, leading to better gross motor function and gait patterns in children with and adults post-stroke, as shown in 2024 RCTs with 15-25% gains in balance scores. , like myoelectric upper-limb devices, use electromyographic signals to control movements, offering transformative restoration for limb loss or ; 2025 reviews highlight integrations with AI for , improving user acceptance and precision by 30-50%. Market analyses project continued growth in these AI-enhanced systems, emphasizing their role in neurorehabilitation for motor disorders. Lifestyle modifications, particularly structured exercise regimens, offer accessible, low-risk options for managing motor symptoms. , a mind-body practice emphasizing slow, controlled movements, has been extensively studied for its impact on balance and gait in . Meta-analyses of RCTs reveal that reduces scores by 2-4 seconds, indicating better mobility and a 20-40% decrease in fall incidence after 12-24 weeks, with sustained effects on postural stability. These outcomes stem from enhanced and muscle coordination, making a recommended adjunct for long-term motor maintenance across various motor disorders.

Epidemiology and Prognosis

Prevalence and Distribution

Motor disorders, encompassing conditions such as (PD), (ALS), , , and , exhibit varying global prevalence rates that reflect their distinct etiologies and . For PD, a prevalent neurodegenerative motor disorder, the global estimate exceeded 8.5 million cases in 2019, with prevalence rates reaching approximately 9.34 cases per 1,000 individuals over age 60, underscoring its strong association with aging. In contrast, ALS, a progressive motor neuron disease, maintains a lower global prevalence of 2-5 cases per 100,000 population, as derived from Global Burden of Disease (GBD) analyses. Essential tremor affects approximately 0.4–4% of adults over 40 years, while Huntington's disease has a prevalence of 5–10 cases per 100,000 globally. These figures highlight the rarity of ALS and Huntington's relative to PD and essential tremor, while dystonia, characterized by involuntary muscle contractions, shows an overall prevalence of approximately 31 cases per 100,000 for idiopathic or inherited isolated forms, with primary subtypes being the most common. Geographic variations in motor disorder prevalence are influenced by genetic and environmental factors. Dystonia rates appear higher among populations of European descent, with late-onset forms estimated at 283 per million in Europeans compared to lower rates in first-generation migrants from and , potentially linked to differences in genetic pools such as variants in the DYT1 gene. In , epidemiological studies in report dystonia prevalence at least 10.1 per 100,000, comparable to Western estimates but with phenotypic differences, such as higher facial dystonia. For PD and ALS, regional disparities are less pronounced globally but show elevated burdens in high-income areas with older demographics, per GBD 2021 data. Demographic trends indicate rising motor disorder due to global aging and increased . Age-adjusted rates for PD have increased significantly from 1990 to 2021, driven by a 24-25% contribution from aging populations in GBD assessments, with projections estimating over 25 million cases worldwide by 2050. differences are notable, particularly in , where males experience higher incidence and prevalence rates across age groups under 69, as evidenced by GBD 2021 decompositions. These patterns, informed by recent GBD studies and WHO data, emphasize the need for targeted surveillance in aging societies. Distributions of risk factors, including exposures, vary between urban and rural settings, contributing to heterogeneous . Rural areas often show higher and heavy metal exposures linked to agricultural work, elevating PD risk, while urban environments correlate with increased and traffic-related toxins that may exacerbate motor degeneration in disorders like . Such disparities underscore environmental influences on motor disorder , with GBD analyses highlighting their role in burden variations across socioeconomic contexts.

Long-Term Outcomes

Long-term outcomes for individuals with motor disorders vary significantly depending on the specific condition, but they generally involve progressive , reduced survival in some cases, and diminished . In (PD), effective treatment can extend , with many patients surviving 10 to 20 years or longer post-diagnosis, though overall is reduced by approximately 6 to 7 years compared to age-matched controls without the disease. In contrast, (ALS) is characterized by a more rapid decline, with a median survival of 30 to 36 months from symptom onset, though about 20% of patients live beyond 5 years and 10% beyond 10 years. Disability in motor disorders progresses variably, often leading to increased dependency over time. In PD, the provides a framework for staging this progression, starting from stage 1 (unilateral symptoms without balance impairment) to stage 5 (confinement to bed or , requiring substantial assistance for all activities). Longitudinal analyses indicate that transitions between stages, such as from 3 (moderate bilateral symptoms with some postural instability) to 4 (severe disability with inability to walk or stand unassisted), occur at a median rate of several years, culminating in advanced dependency for the majority of patients. Quality of life in motor disorders deteriorates progressively, particularly in domains affected by mobility and daily functioning. The Questionnaire-39 (PDQ-39) is a validated tool that reveals significant declines in mobility scores over time in PD patients, with average reductions of 10-20 points in this domain after 2-5 years of follow-up, influenced by factors such as comorbidities, mood disturbances, and non-motor symptoms. Similar patterns emerge in , where mobility impairments contribute to broader quality-of-life decrements, though disease rapidity limits long-term assessments. Prognostic factors play a critical role in shaping long-term trajectories, with early intervention emerging as a key modifier in longitudinal studies. In PD, initiating high-intensity early after has been shown to slow motor progression and preserve over 12 months or more, as evidenced by reduced declines in Unified Rating Scale scores in randomized trials. For , early use of is associated with extended survival, particularly in fast-progressing cases, adding 3-6 months to median expectancy based on real-world cohort data from 2020-2025. Other predictors include age at onset (younger in PD linked to longer survival but higher risk), bulbar involvement in ALS (shorter survival), and biomarkers like light chain levels, which forecast decline rates in prospective studies. These factors underscore the importance of timely, multifaceted management to optimize outcomes.

References

  1. https://www.mayoclinic.org/diseases-conditions/movement-disorders/symptoms-causes/syc-20363893
  2. https://medlineplus.gov/movementdisorders.html
  3. https://nba.uth.tmc.edu/neuroscience/m/s3/chapter06.html
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3064755/
  5. https://www.medlink.com/news/jean-martin-charcot-the-father-of-modern-neurology
  6. https://pubmed.ncbi.nlm.nih.gov/19892136/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8875209/
  8. https://www.sciencedirect.com/science/article/pii/B9780444534866000491
  9. https://my.clevelandclinic.org/health/diseases/24847-movement-disorders
  10. https://icd.who.int/browse/2024-01/mms/en
  11. https://www.psychiatry.org/patients-families/neurodevelopment-disorders/neurodevelopmental-disorders-motor-disorders
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7833604/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11846774/
  14. https://www.askbio.com/askbio-announces-publication-of-complete-results-of-phase-1b-trial-of-ab-1005-gene-therapy-in-participants-with-parkinsons-disease-in-movement-disorders/
  15. https://www.merckmanuals.com/professional/neurologic-disorders/movement-and-cerebellar-disorders/overview-of-movement-and-cerebellar-disorders
  16. https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6178705/
  18. https://practicalneurology.com/diseases-diagnoses/movement-disorders/movement-disorders-moment-pain-palliative-care-in-movement-disorders/31795/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5673689/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5567218/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC10429746/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8350038/
  23. https://www.ncbi.nlm.nih.gov/books/NBK536715/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4850743/
  25. https://www.mayoclinic.org/diseases-conditions/tourette-syndrome/symptoms-causes/syc-20350465
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6174447/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC10785957/
  28. https://www.ncbi.nlm.nih.gov/books/NBK1305/
  29. https://pubmed.ncbi.nlm.nih.gov/18418676/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6554265/
  31. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-024-00794-w
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC11982189/
  33. https://www.ncbi.nlm.nih.gov/books/NBK1492/
  34. https://pubmed.ncbi.nlm.nih.gov/17503336/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC5082606/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4515672/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5345642/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4684089/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3775622/
  40. https://www.cdc.gov/traumatic-brain-injury/data-research/facts-stats/index.html
  41. https://www.ajog.org/article/S0002-9378(08)00776-X/fulltext
  42. https://www.nature.com/articles/jp201778
  43. https://www.ncbi.nlm.nih.gov/books/NBK537141/
  44. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2023.1242929/full
  45. https://jamanetwork.com/journals/jamaneurology/fullarticle/793103
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4347949/
  47. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2013.00083/full
  48. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-023-00378-6
  49. https://www.aans.org/patients/conditions-treatments/parkinsons-disease/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7900407/
  51. https://www.neurology.org/doi/10.1212/WNL.90.15_supplement.P6.031
  52. https://journals.physiology.org/doi/10.1152/nips.01363.2001
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11251871/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7734299/
  55. https://pubmed.ncbi.nlm.nih.gov/6249894/
  56. https://www.ncbi.nlm.nih.gov/books/NBK556151/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC10632209/
  58. https://www.ncbi.nlm.nih.gov/books/NBK560582/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4024417/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC490629/
  61. https://www.ncbi.nlm.nih.gov/books/NBK563178/
  62. https://www.ncbi.nlm.nih.gov/books/NBK564383/
  63. https://academic.oup.com/book/24976/chapter/188908307
  64. https://www.movementdisorders.org/MDS/MDS-Rating-Scales/MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-UPDRS.htm
  65. https://med.stanford.edu/stanfordmedicine25/the25/parkinsondisease.html
  66. https://practicalneurology.com/diseases-diagnoses/movement-disorders/evaluation-of-patients-with-tremor/30247/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4749352/
  68. https://www.mayoclinic.org/diseases-conditions/movement-disorders/diagnosis-treatment/drc-20567986
  69. https://www.sralab.org/rehabilitation-measures/international-cooperative-ataxia-rating-scale
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC8213578/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC7722013/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC8877967/
  73. https://www.apdaparkinson.org/article/what-is-a-datscan-and-should-i-get-one/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC6630131/
  75. https://www.aafp.org/pubs/afp/issues/2021/0601/p647.html
  76. https://www.mayocliniclabs.com/test-catalog/overview/617571
  77. https://www.ncbi.nlm.nih.gov/gtr/tests/551813/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC6125576/
  79. https://emedicine.medscape.com/article/1170097-workup
  80. https://www.ncbi.nlm.nih.gov/books/NBK611987/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC12384595/
  82. https://www.nature.com/articles/s41531-025-01146-1
  83. https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.30318
  84. https://www.ncbi.nlm.nih.gov/books/NBK482140/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2600052/
  86. https://www.uptodate.com/contents/medical-management-of-motor-fluctuations-and-dyskinesia-in-parkinson-disease
  87. https://www.ncbi.nlm.nih.gov/books/NBK519488/
  88. https://reference.medscape.com/drug/trihexyphenidyl-343054
  89. https://clinicalmovementdisorders.biomedcentral.com/articles/10.1186/s40734-016-0047-6
  90. https://pubmed.ncbi.nlm.nih.gov/17876242/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC6440024/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC10148791/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC4850731/
  94. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1603233/full
  95. https://www.sciencedirect.com/science/article/pii/S1877065719301071
  96. https://research.aota.org/ajot/article/77/6/7706205020/24998/Efficacy-of-Motor-Interventions-on-Functional
  97. https://unmhealth.org/services/development-disabilities/programs/other-disability-programs/cerebral-palsy-taskforce/_media/case-smith-et-al-2013.pdf
  98. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2821278
  99. https://www.frontiersin.org/journals/neurorobotics/articles/10.3389/fnbot.2024.1443010/full
  100. https://journals.lww.com/atn/fulltext/2025/12000/advances_in_myoelectric_neuroprosthetics__a.6.aspx
  101. https://www.einpresswire.com/article/866227278/artificial-intelligence-ai-enhanced-neurorehabilitation-exoskeleton-market-forecasted-to-achieve-us-2-42-bn-by-2029
  102. https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-024-02151-5
  103. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102942
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC4306407/
  105. https://www.nejm.org/doi/full/10.1056/NEJMoa1107911
  106. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
  107. https://www.sciencedirect.com/science/article/pii/S2666756824000941
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC10424837/
  109. https://www.ncbi.nlm.nih.gov/books/NBK499841/
  110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882734/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC9547134/
  112. https://tremorjournal.org/articles/10.5334/tohm.170
  113. https://www.researchgate.net/publication/9058252_Epidemiology_of_primary_dystonias_in_Japan_Comparison_with_Western_countries
  114. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1498756/full
  115. https://www.bmj.com/content/388/bmj-2024-080952
  116. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1539889/full
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC12066381/
  118. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00218/full
  119. https://www.sciencedirect.com/science/article/pii/S0013935125014835
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC1386659/
  121. https://www.solace.health/articles/parkinsons-disease-life-expectancy
  122. https://www.verywellhealth.com/life-expectancy-in-parkinsons-disease-4129033
  123. https://www.als.org/understanding-als/stages
  124. https://www.neurology.org/doi/10.1212/WNL.0000000000213467
  125. https://www.physio-pedia.com/Hoehn_and_Yahr_Scale
  126. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.22875
  127. https://www.sralab.org/rehabilitation-measures/parkinsons-disease-questionnaire-39
  128. https://www.nature.com/articles/s41531-021-00256-w
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC11133834/
  130. https://www.tandfonline.com/doi/full/10.1080/21678421.2025.2472889
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC12452497/
  132. https://www.sciencedirect.com/science/article/pii/S2352396424003591
Add your contribution
Related Hubs
User Avatar
No comments yet.